RxDoctor Payments Data

Christopher Sellers, MD

Internal Medicine · Chapel Hill, NCNPI 1205060712

Payments from drug & device makers

$259,195in general payments, 2019–2025

Across 251 payments — averaging $1032.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$254K
  • Theratechnologies Inc.$2K
  • Gilead$1K
  • La Jolla Pharmaceutical Company$824
  • Johnson & Johnson$720
  • Janssen Products, LP$317
  • plus $297 from 3 others

What the payments were for

  • Consulting fees$2,72837%
  • Speaking & faculty fees$541%
  • Food & beverage$4,18157%
  • Education$3174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$259,195 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,067
Medicare patients
43
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala82$329,708
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$116,138
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$86,691
TivicayDolutegravir Sodium37$85,229
DescovyEmtricitabine/Tenofov Alafenam37$81,026
DovatoDolutegravir Sodium/Lamivudine17$48,666
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$38,738
MytesiCrofelemer12$27,953
IsentressRaltegravir Potassium13$25,539
CeftriaxoneCeftriaxone Sodium12$3,326
ValacyclovirValacyclovir Hcl33$1,431
Ventolin HfaAlbuterol Sulfate18$1,010
Gabapentin28$269
Atorvastatin Calcium39$228
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril11$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,436$497,425139 claims
Viiv Healthcare CompanyTivicay, Dovato$253,535$133,89554 claims
Janssen Products, LPSymtuza$317$116,13825 claims
Napo Pharmaceuticals IncMytesi$92$27,95312 claims
MerckIsentress$182$25,53913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →